Allogeneic cell therapy manufacturing: process development technologies and facility design options-Reference-Cited by-同舟云学术

Allogeneic cell therapy manufacturing: process development technologies and facility design options

Published:2017-07-20 Issue:10 Volume:17 Page:1201-1219
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Abbasalizadeh Saeed¹²,Pakzad Mohammad¹,Cabral Joaquim M.S.²,Baharvand Hossein¹³

Affiliation:

1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

2. Department of Bioengineering and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal

3. Department of Developmental Biology, University of Science and Culture, Tehran, Iran

Funder

Iran Science Elites Federation

Iran National Science Foundation

National institute for medical research development

Royan Institute

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2017.1354982

Reference139 articles.

1. Global regenerative medicines market overview. Allied Market Research, 2016.

2. Global biopharmaceuticals market. P&S Market Research, 2015.

3. Annual data report on gene and cellular therapies and the regenerative medicine sector. Washington DC: 2016.

4. Quarterly data report on gene and cell therpies and the regenerative medicine sector-Q3 2016. Washington: Alliance for Regenerative Medicine, 2016.

5. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Source-Cell Storage Systems for Allogeneic Cell Therapy Products: Comparison of the Regulatory Systems in Target Countries;Research in Clinical Pharmacy;2023-06-30

2. 再生医療の細胞製造における上流工程に関する概説;Yamaguchi Medical Journal;2023-05-29

3. Issues with Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union;Tissue Engineering Part B: Reviews;2023-02-01

4. Product-safety considerations in allogeneic chimeric antigen-receptor T-cell process flows;Current Opinion in Biotechnology;2022-12

5. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies;Journal of Hematology & Oncology;2022-11-08